This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called Glepaglutide for patients with Short Bowel Syndrome (SBS). Short Bowel Syndrome is a condition where the body cannot absorb enough nutrients and fluids because a significant portion of the small intestine is missing or not functioning properly. The treatment being tested, Glepaglutide, is a solution for injection that is designed to help improve nutrient absorption in these patients.

The purpose of this study is to evaluate how safe Glepaglutide is for long-term use in people with Short Bowel Syndrome. Participants in the study will receive either Glepaglutide or a placebo, which is a substance with no active medication. The study will monitor participants over a period to observe any changes in their condition and to ensure the treatment is safe. The study will also look at how well the treatment works in reducing the need for parenteral support, which is a method of feeding that bypasses the usual process of eating and digestion.

Throughout the study, participants will receive regular check-ups to monitor their health, including assessments of vital signs, heart function through an electrocardiogram (ECG), and various blood and urine tests. The study aims to see if Glepaglutide can help reduce the volume of parenteral support needed and improve the overall quality of life for those with Short Bowel Syndrome. The trial is expected to continue until 2026, providing valuable information on the long-term use of Glepaglutide in managing this condition.